A. Wakeling

发表

A potent specific pure antiestrogen with clinical potential.

A. Wakeling, M. Dukes, J. Bowler, 1991, Cancer research.

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

K. Gibson, J. Woodburn, S. Ashton, 2002, Cancer research.

The future of new pure antiestrogens in clinical breast cancer

A. Wakeling, 2004, Breast Cancer Research and Treatment.

Consensus Statement : Prevention of Flexible

A. Howell, M. Dowsett, C. Benz, 2005 .

Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones.

A. Wakeling, R. Chester, M. Dukes, 1994, The Journal of endocrinology.

Advances in Brief MCF 7 / LCC 2 : A 4-Hydroxytamoxifen Resistant Human Breast Cancer Variant That Retains Sensitivity to the Steroidal Antiestrogen ICI 182 , 78 o 1

Robert, M. Lippman, A. Wakeling, 2006 .

Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?

A. Wakeling, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780

R. Sutherland, C. K. Watts, J. Zalcberg, 1993, International journal of cancer.

Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer

R. Nicholson, I. Hutcheson, J. Knowlden, 2002, Annals of the New York Academy of Sciences.

Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model.

J. Smyth, S. Langdon, W. Miller, 1994, European journal of cancer.

Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.

A. Wakeling, C. Morris, 2002, Endocrine-related cancer.

Pharmacology of Antiestrogens

A. Wakeling, 1999 .

ICI 182,780 (Faslodex™)

A. Howell, C. Osborne, A. Wakeling, 2000, Cancer.

Biology and mode of action of pure antioestrogens.

A. Wakeling, J. Bowler, 1989, Drugs under experimental and clinical research.

Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer

M. Dowsett, R. Nicholson, Z. Rayter, 2001 .

Use of pure antioestrogens to elucidate the mode of action of oestrogens.

A. Wakeling, A. Wakeling, 1995, Biochemical pharmacology.

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

M. Dowsett, J. Robertson, R. Nicholson, 2001, Cancer research.

Growth factors and their receptors: new targets for prostate cancer therapy.

A. Wakeling, J. Barton, G. Blackledge, 2001, Urology.

ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT

K. Gibson, J. Woodburn, S. Ashton, 1997 .

The Therapeutic Potential of Novel Pure Antiestrogens

A. Wakeling, 1994 .

Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines

I. Marschner, M. Ching, J. Zalcberg, 2004, Cancer Chemotherapy and Pharmacology.

Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells.

A. Wakeling, E. Newboult, S. Peters, 1989, Journal of molecular endocrinology.

Tissue-specific actions of antioestrogens.

A. Wakeling, 1995, Mutation research.

Novel steroidal pure antiestrogens

A. Wakeling, J. Bowler, T. J. Lilley, 1989, Steroids.

The pure antiestrogen ICI 182,780 binds to a high‐affinity site distinct from the estrogen receptor

R. Sutherland, J. Zalcberg, A. Wakeling, 1995, International journal of cancer.

3 Mechanisms of growth regulation of human breast cancer

A. Wakeling, 1990 .

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib ( ZD 1839 ; Iressa ) in human breast and prostate cancer cells

R. Nicholson, M. Rubini, S. Hiscox, 2004 .

Steroidal pure antioestrogens.

A. Wakeling, J. Bowler, 1987, The Journal of endocrinology.

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

S. Hilsenbeck, C. Osborne, A. Wakeling, 2004, Cancer Chemotherapy and Pharmacology.

Insecticide Inhibition of 5α-Dihydrotestosterone Binding in the Rat Ventral Prostate

W. J. Visek, A. Wakeling, W. Visek, 1973, Science.

New EGF‐R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC‐3 and DU‐145

R. Nicholson, D. Barrow, A. Wakeling, 1997, International journal of cancer.

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

R. Nicholson, S. Hiscox, D. Barrow, 2004, Clinical & Experimental Metastasis.

Circumvention of doxorubicin resistance in multi-drug resistant human leukaemia and lung cancer cells by the pure antioestrogen ICI 164384.

T. Martin, J. Zalcberg, A. Wakeling, 1991, European journal of cancer.

MCF‐7 human mammary adenocarcinoma cell death in vitro in response to hormone‐withdrawal and dna damage

J. Hickman, C. Dive, A. Wakeling, 1995, International journal of cancer.

Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes

A. Howell, M. Dowsett, R. Blamey, 1996, Breast Cancer Research and Treatment.

Pure Antiestrogens The Most Important Advance in the Endocrine Therapy of Breast Cancer since 1896? a

C. Osborne, R. Nicholson, J. Knowlden, 1996, Annals of the New York Academy of Sciences.

Pure Antioestrogens — A New Horizon in Breast Cancer Therapy?

A. Wakeling, 1994 .

Interactions Between Growth Factors and Oestrogens in Breast Cancer Cells

A. Wakeling, 1993 .

Therapeutic potential of pure antioestrogens in the treatment of breast cancer

A. Wakeling, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells.

A. Wakeling, 1989, Journal of steroid biochemistry.

Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging.

A. Wakeling, M. Dukes, J. Waterton, 1993, The Journal of endocrinology.

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

S. Hilsenbeck, C. Osborne, P. Brown, 2004, Journal of the National Cancer Institute.

A rationalization of the effects of anti-oestrogens and oestrogens on uterine RNA synthesis in the immature rat.

A. Waters, A. Wakeling, J. Knowler, 1983, Journal of steroid biochemistry.

New targets for therapeutic attack

J. Woodburn, A. Barker, D. S. Brown, 1997 .

The isolation of recombinant RNA species responsive to oestrogen and tamoxifen in rat uterus and MCF-7 cells

A. Wakeling, J. Knowler, M. Travers, 1988, Molecular and Cellular Endocrinology.

Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys.

J. Waterton, A. Wakeling, M. Dukes, 1992, The Journal of endocrinology.

Prostaglandin receptors in the human, monkey and hamster uterus.

A. Wakeling, L. Wyngarden, 1974, Endocrinology.

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

R. Nicholson, M. Rubini, S. Hiscox, 2004, Endocrine-related cancer.

Novel antioestrogens without partial agonist activity.

A. Wakeling, J. Bowler, 1988, Journal of steroid biochemistry.

Pharmacology and clinical uses of inhibitors of hormone secretion and action

A. Wakeling, B. Furr, 1987 .

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

R. Nicholson, I. Hutcheson, J. Knowlden, 2001, Endocrine-related cancer.

ICI 182,780, a new antioestrogen with clinical potential

A. Wakeling, J. Bowler, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

R. Schiff, C. Osborne, H. Weiss, 2004, Journal of the National Cancer Institute.

Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor*

S. Korsmeyer, M. O'hare, C. Streuli, 2002, The Journal of Biological Chemistry.

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

R. Nicholson, J. Gee, I. Hutcheson, 2003, Endocrinology.

The EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is an effective inhibitor of tamoxifen-resistant breast cancer growth

R. Nicholson, I. Hutcheson, J. Knowlden, 2001 .

Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle.

R. Sutherland, E. Musgrove, A. Wakeling, 1989, Cancer research.

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

C. Osborne, R. Nicholson, C. Osborne, 2004, British Journal of Cancer.

Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells

R. Nicholson, J. Gee, I. Hutcheson, 2003, Breast Cancer Research and Treatment.

Effects of dieldrin on 5 -dihydrotestosterone binding in the cytosol and nucleus of the rat ventral prostate.

W. J. Visek, A. Wakeling, T. Schmidt, 1973, Toxicology and applied pharmacology.

erbB Signalling and Endocrine Sensitivity of Human Breast Cancer

R. Nicholson, J. Robertson, A. Wakeling, 1997 .

Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancer a

B. Katzenellenbogen, R. Nicholson, M. Montano, 1995, Annals of the New York Academy of Sciences.

EFFECT OF NORETHYNODREL ON SPONTANEOUS OVULATION AND FERTILIZATION IN ADULT FEMALE RATS.

A. Wakeling, 1965, Journal of reproduction and fertility.

In vitro and in vivo effects of a luteolytic prostaglandin (Estrumate, I.C.I. 80996) on rat ovarian adenylate cyclase activity.

A. Wakeling, L. Green, 1981, Biochemical Society transactions.

Corpus luteum prostaglandin receptors and luteolysis.

A. Wakeling, L. Green, 1981, Acta veterinaria Scandinavica. Supplementum.

Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer.

R. Blamey, R. Nicholson, J. Robertson, 1996, European journal of cancer.

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

S. Hilsenbeck, C. Osborne, R. Nicholson, 1995, Journal of the National Cancer Institute.

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.

R. Nicholson, J. Gee, I. Hutcheson, 2003, Endocrinology.

Epidermal growth factor receptor tyrosine kinase inhibitors.

A. Wakeling, 2002, Current opinion in pharmacology.

MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.

R. Clarke, M. Lippman, A. Wakeling, 1993, Cancer research.

Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells

R. Nicholson, D. Barrow, A. Wakeling, 2004, Breast Cancer Research and Treatment.

A. Wakeling, A. Wakeling, 2000, Endocrine-related cancer.

Tamoxifen-induced changes in the polyribosomes and associated mRNA of rat uterus

A. Waters, A. Wakeling, J. Knowler, 1983, Molecular and Cellular Endocrinology.

Therapeutic Potential of Tyrosine Kinase Inhibitors in Breast Cancer

A. Wakeling, C. Morris, S. Averbuch, 2003, Cancer investigation.

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

S. Hilsenbeck, R. Schiff, C. Osborne, 2006, Cancer research.

New Antioestrogens Without Oestrogenic Activity

A. Wakeling, 1989 .

Effect of arginine deficiency on growth and intermediary metabolism in rats.

W. J. Visek, J. Milner, A. Wakeling, 1974, The Journal of nutrition.

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.

Motonori Yamaguchi, Kaoru Kondo, A. Wakeling, 2003, Anticancer research.

Prostaglandin specific binding in the rabbit oviduct.

A. Wakeling, C. Spilman, 1973, Prostaglandins.

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

J. Woodburn, A. Barker, D. S. Brown, 2005, Breast Cancer Research and Treatment.

Prospects for combining hormonal and nonhormonal growth factor inhibition.

R. Nicholson, J. Gee, A. Wakeling, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibitors of growth factor signalling.

A. Wakeling, A. Wakeling, 2005, Endocrine-related cancer.

Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase

A. Wakeling, 2005 .

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

S. Hilsenbeck, C. Osborne, P. Brown, 2004, Journal of the National Cancer Institute.

Development of novel oestrogen-receptor antagonists.

A. Wakeling, J. Bowler, 1991, Biochemical Society transactions.

The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancer

J. Patterson, A. Wakeling, B. Furr, 1982, Breast Cancer Research and Treatment.

The potential for a novel pure anti-oestrogen.

A. Wakeling, 1989, Hormone research.

In vitro studies on the nature of prostaglandin E1 binding in the hamster uterus.

A. Wakeling, L. Wyngarden, 1974, Prostaglandins.

Prostaglandin receptors in the hamster uterus during the estrous cycle.

A. Wakeling, K. Kirton, 1973, Prostaglandins.

Pure antioestrogens in breast cancer - experimental and clinical observations

A. Howell, M. Dowsett, R. Mansel, 1994 .

Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells

B. Katzenellenbogen, R. Nicholson, A. Wakeling, 1995 .

Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment.

S. Pinder, K. Cheung, E. Gutteridge, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological markers during early treatment of tamoxifen resistant breast cancer with gefitinib ('Iressa')[Abstract]

R. Nicholson, E. Gutteridge, J. Robertson, 2004 .

Inhibitors of Protein Kinases and Protein Phosphates Contributors

L. Meijer, D. Fabbro, M. Yacoub, 2005 .

Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor

R. Nicholson, D. Barrow, A. Wakeling, 2002, The Prostate.

ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]

R. Nicholson, I. Hutcheson, J. Knowlden, 2001 .

Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.

A. Lykkesfeldt, L. Wiseman, A. Wakeling, 1993, European journal of cancer.

Steroid antagonists as nuclear receptor blockers.

A. Wakeling, 1992, Cancer surveys.